Shanghai Zhiyuan Biotechnology

Shanghai Zhiyuan Biotechnology is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative small molecule drugs for oncology and inflammatory diseases. The company focuses on modulating the innate immune system, leveraging a proprietary drug discovery platform to target pathways previously considered difficult to drug. Its lead clinical candidate, ZY-022, is a potent dual agonist of Toll-like receptor 7 (TLR7) and Toll-like receptor 8 (TLR8), currently being evaluated in Phase 1 trials for advanced solid tumors. Headquartered in Shanghai's Zhangjiang Hi-Tech Park, the company is supported by leading venture capital firms including Qiming Venture Partners and Sequoia China. Shanghai Zhiyuan Biotechnology aims to advance the field of immunotherapy by providing novel treatments that can overcome resistance to current standard-of-care therapies.